Clinical trials

#Biopharmaceuticals #Biotechnology #Clinical trials #Covid-19 #Podcast #Sitting Down With

Clinical trials and the growing importance of technology

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Read More

#Podcasts

#Clinical trials #Neurology #Rare disease

First patient enrollment for ALS treatment trial 

Ferrer, a pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has enrolled the first patient in its Amyotrophic Lateral Sclerosis (ALS) Deceleration with ORal Edaravone (ADORE), FNP122 Phase III clinical trial.   The trial   The trial will enrol about 300 patients across European countries and it will evaluate… Read More

#News #Trending News

#Clinical trials #Covid-19 #GlobalData

UK falls behind other countries in clinical trial activity 

While trial activity has since recovered to pre-Covid-19 pandemic levels in Australia and the US, the UK remains behind, according to reporting by Andrew Hillman, healthcare and pharmaceuticals data journalist at GlobalData.  Hillman explained that the UK commenced 18% fewer commercial trials during the first three quarters of 2021 than… Read More

#Covid-19 #News #Trending News

#Cancer research #Clinical trials #Drug discovery #Oncology #T-Cells #Tumours

HOOKIPA advances to Phase II trials for treatment of head and neck cancer 

HOOKIPA Pharma is advancing HB-201 to Phase II to be evaluated in combination with pembrolizumab as first or second-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC).   Interim Phase I data in heavily pre-treated patients continue to show HB-200 monotherapy (both… Read More

#News

#Cancer research #Clinical trials #Rare disease #Research

Accelerating research: the path forward for treating rare cancers 

Listen to this article on the DDW Podcast: RareCan is a new company based in the UK. Its aim is to accelerate research into rare cancers. However, finding suitable patients willing to take part in research and trials of new drugs is difficult, which impacts the discovery process. Professor Andy Hall, Founding Director and… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines

T-cell vaccines may offer “significant benefits” over current Covid-19 vaccines 

Emergex Vaccines has announced that it has received the necessary regulatory approvals to initiate a Phase I clinical trial to evaluate the safety and tolerability of its vaccine candidate for SARS-CoV-2.  The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high… Read More

#Covid-19 #News

#Clinical trials #CRO #Pharmaceuticals #Research

Advantages of working with CROs in Central and Eastern Europe 

Discover how Central and Eastern Europe (CEE) provides an attractive environment to conduct clinical studies of any phase while partnered with a local CRO in this interview with Research Professionals’ Managing Partner, György Barta (DPharm).  Barta discusses the many benefits of conducting clinical studies in CEE as… Read More

#News

#Clinical trials #Webinar

BioIVT to showcase new model to study drug-drug interactions

BioIVT hosted a webinar in which researchers discussed how they used a sandwich-cultured human hepatocyte (SCHH) model to investigate the drug-drug interaction (DDI) potential of bempedoic acid, a drug that was recently approved to treat hypercholesterolemia.   During Phase II and III trials of bempedoic acid, small, reversible increases in… Read More

#News

#Cancer #Clinical trials #Drug development #Drug therapy

Experimental immunotherapy cancer treatment enters Phase II 

Australian clinical-stage drug development company Noxopharm has announced its DARRT-2 Phase II clinical trial has begun with patient enrollment in the US. It is said to have the potential to revolutionise cancer treatment by achieving cancer reduction without many of the unwanted side effects, cost limitations, and logistical challenges… Read More

#News

#Clinical trials #Data #Technology

Clinical Ink acquires Digital Artefacts 

Clinical Ink, a clinical trial data and technology company, has acquired Digital Artefacts, a digital endpoint-based technology company.   “The addition of Digital Artefacts now allows us to drive situational awareness because context matters. Data derived from Digital Artefacts can now increase the richness of our partners’ study… Read More

#News

#Clinical trials #Data

Pharma and the benefits of Real World Data 

Listen to this article on the DDW Podcast: Karen Ooms, Executive Vice President and Head of Statistics with Quanticate, argues that analysing data from real-life patients has finally come of age.  Statistical consultants have, for a long time, tried to convey to the pharmaceutical industry the merit of using real world data (RWD) to help… Read More

#Exclusive Content #Trends & Analysis

Seed funding
#Alzheimer's #Clinical trials #Drug discovery #Funding

€9 million to address ‘Agitation/Aggression’ in Alzheimer’s

Exciva has closed a Series A financing of €9 million, led by Andera Partners, to develop the lead compound up to completion of Phase I. The product has the potential to treat behavioral and psychological symptoms in Alzheimer disease patients. This compound is the combination of two clinically validated products,… Read More

#News

#Clinical trials #Data #Drug discovery #Life sciences

Clinical trials, the pandemic and technology 

Listen to this article on the DDW Podcast: Chris Sigley, CEO of Arkivum, says the transformation of clinical trials demands a transformed approach to trial data  The pandemic has created manifold challenges for clinical trials, but it has also proved a transformational force. The life sciences sector has succeeded in making a… Read More

#Exclusive Content #Trends & Analysis

Human brain
#Clinical trials #Neuroscience #Pharmacokinetics / Pharmacodynamics

Patients dosed in Phase I trial assessing psychiatric disorders 

Beckley Psytech has dosed the first cohort of volunteers in a clinical trial exploring the safety of its novel formulation of intranasal 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT).  The Phase I study is designed as a double-blind, randomised, single ascending dose study to evaluate the safety and tolerability of a single intranasal dose of… Read More

#News

#Cancer #Cancer research #Clinical trials #Funding

Leucid Bio raises £11.5 million to develop CAR-T cell therapies 

Leucid Biohas raised £11.5 million in a Series A financing round, which will be used to initiate a Phase I trial of its lead candidate, LEU-011, for the treatment of platinum resistant ovarian cancer.  CAR T-cell therapy is a technology in which the patient’s own immune cells are reprogrammed… Read More

#News

#Biotechnology #Clinical trials #Covid-19 #Drug discovery #Pharmaceuticals #Pharmacology

Apeiron Biologics begins Covid-19 trial for inhaled drug candidate

Apeiron Biologics has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection.   The double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria… Read More

#News